- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- LY03004
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Orange, California • Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–23
of 23
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
- Interventions
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Garden Grove, California • Orange, California + 6 more
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depressants, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
- Interventions
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 281 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more
- Conditions
- Major Depressive Disorder
- Interventions
- LY03005, Pristiq
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Eatontown, New Jersey
- Conditions
- Cancer of Prostate
- Interventions
- LY01005, Zoladex
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Anniston, Alabama • Aventura, Florida • Pompano Beach, Florida + 2 more
- Conditions
- Healthy Participants
- Interventions
- LY03015 (LPM3770164 extended-release tablets)
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Los Alamitos, California
- Conditions
- Major Depressive Disorder
- Interventions
- LY03005, Pristiq
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Denosumab
- Biological
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 60 Years to 90 Years · Female only
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Thousand Oaks, California • Hialeah, Florida • Fort Worth, Texas
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- LY03004, Risperdal® Consta®
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Long Beach, California • Orange, California + 7 more
- Conditions
- Major Depression
- Interventions
- LY03005, Pristiq
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Eatontown, New Jersey
- Conditions
- Major Depressive Disorder, Recurrent, Unspecified
- Interventions
- LY03005, Placebo
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Marlton, New Jersey
- Conditions
- Parkinson Disease
- Interventions
- LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection), Neupro 4 mg / 24 Hr. Transdermal Patch
- Drug · Other
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Risperdal® Consta®, LY03004
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Orange County, California • Austin, Texas
- Conditions
- Schizo Affective Disorder, Schizophrenia, Schizoaffective Disorder
- Interventions
- LY03010, Invega Sustenna 156 MG in 1 ML Prefilled Syringe
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Garden Grove, California • Berlin, New Jersey
- Conditions
- Parkinson Disease
- Interventions
- LY03003
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Hallandale, Florida • Atlanta, Georgia
- Conditions
- Parkinson Disease
- Interventions
- LY03003, Neupro 4Mg/24Hr Transdermal Patch
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Major Depressive Disorder
- Interventions
- LY03005
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Parkinson's Disease
- Interventions
- ROTIGOTINE
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Long Beach, California • Hallandale, Florida • Atlanta, Georgia
- Conditions
- SCHIZOPHRENIA 1 (Disorder)
- Interventions
- Paliperidone Palmitate
- Drug
- Lead sponsor
- Alejandro Alva
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Orange, California • Miami, Florida • Chicago, Illinois
- Conditions
- Major Depressive Disorder
- Interventions
- LY03005, Placebo, Meal, Pristiq
- Drug · Other
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Parkinson's Disease
- Interventions
- LY03003, Neupro
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Long Beach, California • Orlando, Florida • Douglasville, Georgia + 2 more
- Conditions
- Schizophrenia Patients
- Interventions
- Paliperidone Palmitate
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Berlin, New Jersey
- Conditions
- Lipid Metabolism Disorder
- Interventions
- XueZhiKang, Lovastatin
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Orange, California